Medios Shares Rise on Ambitious 2031 Growth Targets and Strategic Shift

Shares in Medios, a German pharmaceutical services group, rose as much as 5% on Tuesday after the company unveiled ambitious long-term financial targets for 2031. At its capital markets day, Medios outlined a plan to significantly boost revenue and profitability by focusing on its higher-margin business segments.

New Long-Term Financial Goals

Medios announced it is targeting group revenue of approximately €3.1 billion by 2031, a substantial increase from its 2025 forecast of €2.1 billion. The company also aims for adjusted EBITDA of about €170 million, which would nearly double its 2025 baseline of €87 million.

This growth is expected to drive margin expansion, with the company targeting a group adjusted EBITDA margin of about 5.5% by 2031, up from a 4.2% margin in 2025. According to the company, the growth will be driven by:

• €700 million from organic growth, representing a compound annual growth rate (CAGR) of about 5%.
• €300 million from acquisitions, primarily in its Compounding business.

Strategic Realignment and Acquisitions

Ad

To achieve these targets, Medios is reorganizing its operations into two new segments: Specialty Pharma Supply and Compounding. This new structure replaces its previous three-unit model and will see its international operations integrated into the new segments. The company is discontinuing its Advanced Therapies activities to sharpen its focus.

The strategic shift prioritizes investment in the higher-margin Compounding business, which provides individualized medicines. Supporting this strategy, Medios confirmed it has agreed to acquire a majority stake in Caesar & Loretz (Caelo), a supplier of pharmaceutical raw materials. The company stated that antitrust clearances have been obtained and the deal is expected to close shortly.

Financial Health and Shareholder Returns

Medios reported a healthy balance sheet, with a net debt-to-EBITDA ratio of 1.32 times in the first half of the year, well below its internal ceiling of 2.0 times. The company projects it has a cumulative M&A capacity of approximately €325 million through 2031 while staying within its leverage limits.

Looking ahead, Medios also signaled its intent to return capital to shareholders, stating that share buybacks remain its preferred method. Following the announcements, the company's shares pared some of their initial gains to trade 3.1% higher.